Nadia Harbeck, MD, on Trastuzumab Emtansine and Pertuzumab vs. Trastuzumab, Pertuzumab, and Taxane After Anthracyclines in Early Breast Cancer

Posted: Wednesday, June 24, 2020

Nadia Harbeck, MD, of the University of Munich, discusses data from the phase III KAITLIN trial showing that replacing adjuvant taxane and trastuzumab with trastuzumab emtansine did not significantly improve efficacy or overall safety for patients with high-risk HER2-positive early breast cancer.